Does COVID Affect Blood Work? A Look at Common Changes

COVID-19 can alter blood work across a surprisingly wide range of tests, from basic cell counts to inflammatory markers, organ function panels, and even micronutrient levels. Some of these changes are subtle and resolve within weeks, while others persist for months and serve as warning flags for disease severity. Understanding what shifts to expect on a lab report after a SARS-CoV-2 infection helps put abnormal results in context, whether you are dealing with an active case or lingering post-COVID symptoms.

White Blood Cell Shifts and the Complete Blood Count

The most commonly reported change on a standard complete blood count (CBC) during COVID-19 is lymphopenia, meaning your lymphocyte count drops. Lymphocytes are the immune cells responsible for targeted viral defense, and SARS-CoV-2 appears to deplete them in ways that track with how sick you get. Alongside that drop, neutrophils, the immune cells that respond first to any threat, tend to climb. The ratio of neutrophils to lymphocytes (NLR) has become one of the cheapest and most reliable bedside indicators of COVID-19 severity.¹ Patients with severe disease consistently present with more pronounced lymphopenia, higher neutrophil counts, and an NLR that independently predicts ICU admission and mortality.²

Platelet counts also shift, though the direction depends on the stage and severity of illness. Many hospitalized patients develop thrombocytopenia, where platelets drop below normal levels, and the degree of that drop has been linked to worse outcomes and higher mortality risk.³ Immune thrombocytopenia, in which the body’s immune system mistakenly attacks its own platelets, has emerged as a recognized complication of COVID-19.⁴ Even when platelet numbers look normal or only mildly reduced, research has found that COVID-19 platelets behave differently: they are more “sticky,” aggregate more easily, and display surface proteins associated with clotting, giving them a prothrombotic profile that helps explain the elevated clotting risk.⁵

Clotting and Coagulation Markers

One of the more alarming features of COVID-19, particularly in moderate-to-severe cases, is its effect on the coagulation system. D-dimer, a protein fragment produced when blood clots break down, rises sharply in many patients. Elevated D-dimer levels during COVID-19 have been correlated with higher rates of deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation, and those clotting complications track closely with poor outcomes and mortality.⁶ Another coagulation marker, fibrinogen degradation products (FDP), has also shown value as a predictor of severe disease.⁷

What makes COVID-19 unusual compared to many other viral infections is the sheer breadth of its clotting effects. The virus does not just trigger the standard inflammatory cascade that nudges clotting factors upward; it appears to directly affect endothelial cells lining blood vessels, creating a pro-clotting environment throughout the body. That is why clinicians started monitoring D-dimer as a routine part of COVID-19 care fairly early in the pandemic, and why many hospitalized patients received prophylactic blood thinners.

Inflammatory Markers That Spike

If there is a single biochemical theme of COVID-19, it is inflammation. Three inflammatory markers have proven especially useful in gauging severity: C-reactive protein (CRP), ferritin, and interleukin-6 (IL-6).

CRP, a general-purpose inflammation marker produced by the liver, rises substantially in most symptomatic COVID-19 patients. A meta-analysis pooling over 5,300 patients from 25 studies found that elevated CRP was associated with roughly an 84% higher risk of a poor outcome.⁸ Ferritin, an iron-storage protein that also rises during inflammation, showed similarly strong prognostic value in the same analysis. Critically ill patients in one study had mean ferritin levels several times higher than those with milder disease.⁹

IL-6, a cytokine that acts as a key orchestrator of the so-called “cytokine storm,” is perhaps the most studied inflammatory mediator in severe COVID-19. Patients with critical illness have significantly higher serum IL-6 (and IL-10) levels compared to those with moderate or even severe-but-stable disease.¹⁰ IL-6 exerts both pro-inflammatory and anti-inflammatory effects, and it became a direct therapeutic target: the drug tocilizumab, which blocks IL-6 signaling, was used in severe cases specifically to try to tamp down the storm.¹¹ Patients who died also showed significant differences in D-dimer, CRP, ferritin, and IL-18 compared to 30-day survivors, reinforcing that these inflammatory markers together paint a fairly reliable picture of disease trajectory.¹²

Liver, Kidney, and Heart Markers

COVID-19 is not just a lung disease, and organ function panels often reflect that. Liver injury, measured through elevated enzymes like ALT and AST, has been observed in a significant proportion of hospitalized patients, especially in severe or critical illness. Males, older adults, and those with higher body mass index appear more susceptible to COVID-related liver dysfunction, which worsens prognosis and prolongs hospital stays.¹³ The liver damage can occur even in people with no prior liver disease, though those with pre-existing chronic liver conditions face a compounding risk.

Kidney function also takes a hit. Acute kidney injury is a well-documented complication, and lab work commonly shows increased serum creatinine, elevated blood urea nitrogen, and the appearance of protein or blood in the urine.¹⁴ Even in young adults with moderate disease, one study found a trend toward declining kidney filtration rates after infection, suggesting that kidney effects are not limited to the sickest patients.¹⁵ The ratio of blood urea nitrogen to creatinine (BUN/Cr) has even been identified as an independent predictor of disease severity and survival.¹⁶

Cardiac troponin, the gold-standard blood marker for heart muscle damage, is elevated in a notable share of COVID-19 patients and is associated with arrhythmias and death.¹⁷ What is striking is how long the elevation can last. A study tracking troponin I levels found that men older than 54 with even mild COVID-19 had persistently elevated troponin from baseline through at least 9 weeks after diagnosis, and in a subcohort followed longer, the elevation remained at 14 months.¹⁸ Among survivors with acute cardiac injury during hospitalization, fewer than half had recovered normal troponin levels at a follow-up roughly two and a half months later.¹⁹

Blood Sugar and Thyroid Function

Even if you are not diabetic, COVID-19 can push your blood glucose upward. Stress hyperglycemia, driven by the body’s own cortisol surge during acute illness, is one mechanism. When corticosteroids like dexamethasone are used as treatment, the effect is compounded because these drugs oppose insulin action and stimulate the liver to produce more glucose.²⁰ This matters for interpreting HbA1c, the test that reflects average blood sugar over the past two to three months. If HbA1c is checked too soon after recovery (within roughly three months), it may come back falsely elevated due to infection- and treatment-related glucose spikes, not because you have developed diabetes. Clinicians who are aware of this generally wait before drawing conclusions from a post-COVID HbA1c result.

Thyroid function tests show their own pattern of disruption. During hospitalization, low TSH levels were found in about 39% of patients in one study, and half of those patients also had low free T3. In survivors, TSH and free T3 levels generally bounced back by the time of discharge, but in patients who died they stayed permanently low, with free T3 being a predictor of mortality.²¹ More broadly, thyroid dysfunction on admission was present in over half of hospitalized patients in another study, most commonly as what is called non-thyroidal illness syndrome, where thyroid hormone levels drop without the thyroid gland itself being diseased.²² In people with Graves’ disease, COVID-19 infection produced measurable changes in the ratio of thyroid hormones that persisted for at least three months.²³

Vitamin D and Zinc Depletion

Micronutrient panels drawn during active COVID-19 frequently show depleted levels of vitamin D and zinc. In one study of hospitalized patients, 73% were deficient in vitamin D and 52% were deficient in zinc, both significantly worse than in healthy controls.²⁴ A pilot case-control study found that median zinc levels in COVID-19 patients were roughly half those of controls.²⁵ Patients who died tended to have the lowest serum zinc, vitamin D, and vitamin B12 levels at admission, though the differences for vitamin B12 and vitamin D did not always reach statistical significance.²⁶

A word of caution on interpretation: it is not always clear whether low micronutrient levels cause worse COVID-19 outcomes, or whether severe illness itself depletes these nutrients. Both are likely true to some degree. Zinc and vitamin D play genuine roles in immune function, and being deficient going into an infection is probably not helpful. But acute inflammation itself redistributes these nutrients, driving blood levels down even in people whose stores were adequate before they got sick. A low vitamin D reading during a hospital stay does not necessarily mean you were deficient before the virus hit.

Autoantibody Production

One of the more concerning blood work findings is that COVID-19 appears to trigger the production of autoantibodies, proteins that mistakenly target the body’s own tissues. A study comparing COVID-19 patients to healthy controls found that roughly one in every two to three COVID-19 patients tested positive for antinuclear antibodies (ANA), representing about a 2.5-fold increase over controls.²⁷ A separate cohort at the University of Pennsylvania found that about 14% of hospitalized COVID-19 patients were ANA-positive at diagnostically meaningful dilutions, with various patterns suggesting different types of autoimmune targeting.²⁸

These autoantibodies do not always cause symptoms in the short term, but their presence raises the question of whether COVID-19 can serve as a trigger for autoimmune conditions down the line. This connects to the broader observation that post-infectious autoimmunity is not unique to SARS-CoV-2, but the scale at which it seems to happen with this virus has attracted serious research attention.

Long COVID and Persistent Blood Work Abnormalities

For many people, the relevant question is not what happens to blood work during acute infection, but what lingers afterward. The immune fingerprint of long COVID is becoming clearer. A longitudinal study found that people with long COVID had activated monocytes, specific subsets of exhausted CD8+ T cells expressing inhibitory markers (PD-1 and Tim-3), and sustained production of antiviral cytokines at three and eight months after infection. Encouragingly, by 24 months most of these immune markers had normalized, and gene-expression analysis showed no lasting T cell exhaustion signal at that point.²⁹

A separate line of research has focused on microclots: tiny, abnormal fibrin-based clots circulating in the blood of long COVID patients. These microclots are structurally associated with markers shed by neutrophils and are found in elevated amounts in people with persistent symptoms.³⁰ These clots may be resistant to normal breakdown and can trap other proteins, potentially contributing to the fatigue, brain fog, and exercise intolerance that characterize long COVID.³¹ There is also evidence pointing to persistent viral reservoirs and reactivation of latent viruses like Epstein-Barr virus as drivers of the ongoing immune disruption.³²

Standard blood panels may look completely normal in someone with long COVID, which is a source of real frustration for patients and clinicians alike. The microclot and immune-subset findings come from specialized research assays not typically available in routine clinical labs. This mismatch helps explain why many long COVID patients are told their blood work is “fine” when they still feel unwell.

How COVID Blood Work Differs From the Flu

If both COVID-19 and influenza can cause fever, fatigue, and respiratory symptoms, you might wonder whether they look the same on a blood test. They do not. A direct comparison of COVID-19 and influenza B patients found that COVID-19 patients had higher white blood cell and neutrophil counts but lower red blood cell and lymphocyte counts.³³ In children, a study comparing SARS-CoV-2, influenza A, and RSV found that COVID-19 cases had notably higher NLR and platelet counts compared to influenza A, though the overall diagnostic accuracy of any single blood marker was moderate at best.³⁴ In other words, the pattern of shifts can hint at which virus is responsible, but no routine blood test alone definitively distinguishes COVID-19 from influenza. A PCR or antigen test still does the actual identifying.

Vaccination and Blood Work

People sometimes worry that COVID-19 vaccines themselves cause the same blood work abnormalities as the infection. The evidence suggests the changes from vaccination are far smaller in magnitude and shorter in duration. A large study comparing vaccine-associated hematological events to infection-associated events found that the incidence of thrombocytopenia, leukopenia, and neutropenia per 10,000 COVID-19 cases dwarfed the incidence per 10,000 vaccine doses by orders of magnitude. For example, thrombocytopenia occurred in about 1,254 per 10,000 COVID cases, compared to roughly 1 to 3 per 10,000 vaccine doses depending on vaccine type.³⁵ A small, transient risk of leukopenia was observed in the first two weeks following the second dose of BNT162b2 (Pfizer), but even that resolved quickly.

On the flip side, vaccination appeared to produce a favorable shift in red cell distribution width (RDW), a marker that had been associated with worse COVID-19 outcomes. Post-vaccination, RDW actually improved, suggesting more uniform red blood cell production, the opposite of what happens during active infection.³⁶ The takeaway is that vaccination mimics a small, controlled immune response that does not produce the widespread blood work disruption characteristic of actual infection.

Using Routine Blood Tests to Predict Severity

One of the practical legacies of pandemic-era research is the realization that routine blood tests drawn at admission can help predict who is at risk for deterioration. Machine learning models trained on standard lab values identified a combination of five markers, including ferritin, serum iron, prothrombin activity, activated partial thromboplastin time, and monocyte count, that predicted severe disease with reasonable accuracy.³⁷ High-sensitivity CRP and fibrinogen degradation products similarly showed strong predictive power for identifying which patients would progress to severe or life-threatening illness.⁷

None of these markers work in isolation. A single elevated CRP or a mildly low lymphocyte count does not mean you are headed for the ICU. The clinical value comes from looking at the constellation of changes together, in the context of your symptoms, age, and pre-existing conditions. If you are reviewing your own blood work after a COVID-19 infection, the most useful thing is to share the results with your doctor, who can interpret the pattern rather than any individual number.